Cannabinoids Clinical Trials DEA Safety 
Cannabis Law Report
NOVEMBER 22, 2019
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. ”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”
Veriheal
JUNE 30, 2023
For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
APRIL 11, 2022
Drug Enforcement Agency (DEA). We could potentially develop north of 11,000 drugs that are cannabinoid-based. According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. Is the future exciting? Absolutely.”
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision.
Cannabis Law Report
JUNE 4, 2021
We support the Hemp Roundtable’s statements on psychoactive hemp and that it should be regulated separately from hemp, CBD, CBG and other non-psychoactive or non-intoxicating cannabinoids. Delta 8-THC is a psychoactive cannabinoid, just like Delta 9-THC, and legislators should regulate it as such.
SpeedWeed
MARCH 18, 2021
A fourth group received a placebo with almost zero active cannabinoids. for the production of cannabis used in federally-regulated clinical trials. Wasn’t the DEA going to let others grow research-grade cannabis? Another group received an 11% CBD product with minimal THC. Participants were given 1.8
Veriheal
AUGUST 31, 2020
However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinical trials. Supply chains are disrupted as a result, and consumers grow fearful of buying hemp.
Expert insights. Personalized for you.
66 
Let's personalize your content